Skip to main content
. 2014 Dec 23;15:452. doi: 10.1186/1471-2474-15-452

Figure 4.

Figure 4

Schedule of events for subcutaneous biologic DMARDs (etanercept, adalimumab, certolizumab pegol, abatacept, golimumab).